Piper Sandler Starts Avalo Therapeutics Inc. (AVTX) at Overweight

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Avalo Therapeutics Inc. (NASDAQ: AVTX) with a Overweight rating and a price target of $48.00.

The analyst commented: "We are initiating coverage on Avalo Therapeutics with an OW rating and $48 PT. We believe it is currently undervalued with a market cap ~$70M and has AVTX-009, a differentiated anti-IL-1β mAb in hand with key upcoming Ph2 LOTUS readout in 2026. Accordingly, we have a high PoS for AVTX-009 development in hidradenitis suppurativa (HS) with clear IL-1β mechanistic rationale and a large market opportunity. Moreover, AVTX is trading at a significant discount vs MLTX (not covered) which has a market cap of ~$2.7B and is a key contender in the HS landscape. With this, AVTX-009 is already de-risked in HS, and thus we have strong conviction for its success in Ph2 LOTUS with differentiated Q2W/Q4W dosing."

For an analyst ratings summary and ratings history on Avalo Therapeutics Inc. click here. For more ratings news on Avalo Therapeutics Inc. click here.

Shares of Avalo Therapeutics Inc. closed at $6.60 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Full Circle Lithium closes $5.14M private placement